Springer Nature
40425_2019_765_MOESM8_ESM.jpg (46.14 kB)

MOESM8 of Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

Download (46.14 kB)
posted on 2019-10-30, 18:16 authored by Gareth Healey, Belen Pan-Castillo, Jezabel Garcia-Parra, Julia Davies, Shaun Roberts, Eilir Jones, Kalyan Dhar, Sarika Nandanan, Nasima Tofazzal, Luke Piggott, Richard Clarkson, Gillian Seaton, Asa Frostell, Tim Fagge, Colin McKee, Lavinia Margarit, R. Conlan, Deyarina Gonzalez
Additional file 8: Figure S6. RBGO2, RBGO3 and RBGO4 preferentially target endometrial cancer cells and increase drug sensitivity by up to 40-fold.


Welsh Government (A4B Programme)